Interaction of LRRK2 with kinase and GTPase signaling cascades by Joon Y. Boon et al.
REVIEW ARTICLE
published: 09 July 2014
doi: 10.3389/fnmol.2014.00064
Interaction of LRRK2 with kinase and GTPase signaling
cascades
JoonY. Boon1, Julien Dusonchet 1, Chelsea Trengrove1 and Benjamin Wolozin1,2*
1 Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA
2 Neurology, Boston University School of Medicine, Boston, MA, USA
Edited by:
Jean-Marc Taymans, KU Leuven,
Belgium
Reviewed by:
R. Jeremy Nichols, The Parkinson’s
Institute, USA
Patrick Lewis, University College
London, UK
*Correspondence:
BenjaminWolozin, Department of
Pharmacology and Experimental
Therapeutics, Boston University
School of Medicine, 72 East Concord
Street, R614, Boston,
MA 02118-2526, USA
e-mail: bwolozin@bu.edu
LRRK2 is a protein that interacts with a plethora of signaling molecules, but the complexity
of LRRK2 function presents a challenge for understanding the role of LRRK2 in the
pathophysiology of Parkinson’s disease (PD). Studies of LRRK2 using over-expression in
transgenic mice have been disappointing, however, studies using invertebrate systems
have yielded a much clearer picture, with clear effects of LRRK2 expression, knockdown
or deletion in Caenorhabditis elegans and Drosophila on modulation of survival of
dopaminergic neurons. Recent studies have begun to focus attention on particular signaling
cascades that are a target of LRRK2 function. LRRK2 interacts with members of the
mitogen activated protein kinase (MAPK) pathway and might regulate the pathway action
by acting as a scaffold that directs the location of MAPK pathway activity, without strongly
affecting the amount of MAPK pathway activity. Binding to GTPases, GTPase-activating
proteins and GTPase exchange factors are another strong theme in LRRK2 biology, with
LRRK2 binding to rac1, cdc42, rab5, rab7L1, endoA, RGS2, ArfGAP1, and ArhGEF7.
All of these molecules appear to feed into a function output for LRRK2 that modulates
cytoskeletal outgrowth and vesicular dynamics, including autophagy.These functions likely
impact modulation of α-synuclein aggregation and associated toxicity eliciting the disease
processes that we term PD.
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INTRODUCTION
Parkinson’s disease (PD) is the most common age-related motor
disorder (Hsu et al., 2010a; Ferree et al., 2012). Accumulation of
aggregated α-synuclein to form Lewy bodies is a neuropathologi-
cal hallmark for PD (Lees et al., 2009). Mutations in leucine-rich
repeat kinase 2, LRRK2, gene are common genetic determinants of
PD, with at least 20 different mutations identiﬁed to date causing
late-onset, familial autosomal-dominant PD (Gasser et al., 2011;
Greene, 2012). The most prevalent amino acid substitution muta-
tion in LRRK2, G2019S, has been found in 1–2% of sporadic PD
cases; with sporadic PD and LRRK2-associated PD being clinically
and neurochemically indistinguishable (Healy et al., 2008). These
all indicate that LRRK2 has an important role in the pathogenesis
of PD.
LRRK2 is a large ubiquitous cytoplasmic protein consisting
of 2527 amino acids with multiple functional domains (Cook-
son, 2010). LRRK2 has a homolog in mammals, termed LRRK1;
LRRK1 and 2 expression appear to be complementary, with
LRRK2 expression peaking in development and decreases rapidly
after birth, while LRRK2 expression increases postnatally (Simon-
Sanchez et al., 2006). The LRRK2 protein consists of kinase,
Ras-of-complex proteins (ROCs) GTPase, C-terminal of ROC
(COR), leucine-rich repeat, ankyrin and WD40 domains (Cook-
son, 2010). The two catalytic domains are the kinase and ROC
GTPase domains. The kinase domain has the highest sequence
homology to mitogen-activated protein kinase kinase kinase
(MKKK)/MLKs (mixed lineage kinases) and receptor-interacting
protein (RIP) kinase families. The most common mutation in
LRRK2 associated with PD is the G2019S mutation located in
the kinase domain of LRRK2 (Wszolek et al., 2004; Zimprich
et al., 2004). Other common amino acid substitution include
R1441C/G/H in the Roc GTPase domain and Y1699C in the COR
domain (Taylor et al., 2006). The pathological mutations G2019S
enhances the kinase activity without affecting the GTPase activ-
ity of LRRK2; whereas R1441C/G/H and Y1699C affect GTPase
activity of LRRK2 by impairing GTP hydrolysis and has inconsis-
tent effects on its kinase activity (West et al., 2005; Greggio et al.,
2006; Ito et al., 2007; Lewis et al., 2007; Li et al., 2007). However,
the underlying mechanisms linking such mutations to pathology
still remain unclear.
LRRK2 MODULATES SURVIVAL OF DOPAMINERGIC
NEURONS, AUTOPHAGY, AND NEURONAL OUTGROWTH
Studies of LRRK2 using over-expression in transgenic mice have
been disappointing, with few studies showing consistent effects
occurring upon over-expression of wildtype or mutant LRRK2
(Dawson et al., 2010). Knockout of LRRK2 in the mouse yielded
a strong phenotype in the kidney pointing to a role for LRRK2 in
autophagy, however, no clear differences in the brain; this sug-
gests that mammalian LRRK2 in vivo models do a better job
of modeling cellular function/dysfunction rather than provid-
ing a more general model of PD (Tong et al., 2010). In contrast,
over-expression studies using invertebrate systems have yielded
much clearer results. Orthologs of LRRK2 also exist in Drosophila
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and Nematodes, although these species exhibit just one form
of LRRK, referred to as lrk-1 (Marin, 2008). The invertebrate
LRRK2 orthologs have kinase, COR and ROC domains that are
homologous tomammalian LRRK2, and the lrk-1 protein appears
to subsume the functions of both LRRK1 and LRRK2 (Marin,
2008; Saha et al., 2009). Studies from several groups examin-
ing the effects of LRRK2 expression, knockdown or deletion in
Caenorhabditis elegans and Drosophila all show strong effects (Liu
et al., 2008;Wang et al., 2008; Saha et al., 2009; Samann et al., 2009;
Venderova et al., 2009; Yao et al., 2010; Yuan et al., 2011). The
results appear to differ somewhat based on the system, but the
effects are strong in all cases. Studies in our laboratory indicate
that expressing WT LRRK2 promotes survival of dopaminergic
neurons in response rotenone treatment, while mutant LRRK2
(G2019S or R1441C) enhances loss of dopaminergic neurons rel-
ative to WT (Saha et al., 2009). Another important aspect of our
observations, which becomes important when considering studies
of LRRK2 more generally, is that G2019S also potentiates loss of
neuronal processes relative to WT LRRK2. Because nematodes
lack endogenous α-synuclein, we recently crossed the LRRK2
lines to a line expressing α-synuclein in dopaminergic neurons.
Interestingly, current studies with a new nematode model in our
laboratory shows that both WT and G2019S LRRK2 potentiate
age-related loss of dopaminergic neurons (and of their processes),
suggesting that understanding the interaction between LRRK2
and α-synuclein is important for modeling the pathophysiol-
ogy of PD. Studies from the Chen laboratory using a different
C. elegans model (without incorporation of α-synuclein) show a
deleterious effect of WT and G2019S LRRK2, while studies using
Drosophila indicate that LRRK2 potentiates degeneration of reti-
nal cells and loss of dopaminergic neurons (Liu et al., 2008; Yao
et al., 2010). Thus, the speciﬁc results depend on the particular
model used, but it is clear that invertebrate models are very sen-
sitive to modulation of LRRK2 levels, and mutations in LRRK2
potentiate degeneration of dopaminergic neurons. While mouse
models are not particularly sensitive to LRRK2 over-expression,
knockout of LRRK2 appears to potentiate autophagic deﬁcits in
the kidney, which is a site that normally exhibits strong expres-
sion of LRRK2. This provides evidence that the effects observed
with invertebrate systems have strong relevance to themammalian
system.
Studies using primary rodent neurons grown in culture have
yielded much stronger results than the transgenic mouse mod-
els. These studies consistently indicate that expression of mutant
LRRK2 potentiates neurodegeneration, and reduces neurite out-
growth (Smith et al., 2005; Chan et al., 2011; Skibinski et al., 2014).
Interestingly, acute expression of WT LRRK2 appears to be bene-
ﬁcial, which parallels observations from our studies in C. elegans.
One study, using in utero electroporation of LRRK2 in the rodent
brain also observed detrimental effects of G2019S LRRK2 and
beneﬁcial effects of WT LRRK2, suggesting that acute expres-
sion of LRRK2 in the rodent brain might produce clearer results
than chronic over-expression, such as occurs with transgenic mice
(Macleod et al., 2006). Taken together, these results indicate that
mutant LRRK2 is detrimental; the effects of WT LRRK2 are less
clear, with some data suggesting that WT LRRK2 is beneﬁcial,
and other data suggesting that over-expression can be mildly
detrimental. In general, most data suggest that loss of LRRK2
expression is detrimental.
LRRK2 REGULATES MAP KINASE SIGNALING PATHWAYS
Incorporating research from multiple different venues suggests
roles for LRRK2 in two differing cellular networks. Prior studies
from our laboratory, and subsequent studies from the Kahle lab-
oratory indicate that LRRK2 interacts with the mitogen activated
protein kinase (MAPK) pathways (Carballo-Carbajal et al., 2010;
Hsu et al., 2010a,b). The MAPK pathway is a signaling network
that begins with membrane signaling and extends through mul-
tiple successive kinases leading ultimately to phosphorylation of
transcription factors that act on gene expression (Yang et al., 2013).
Receptor signaling frequently begins with MAP Kinase kinase
kinases (MAPKKKs, also termed mixed lineage kinases, MLKs),
which are enzymes often act to initiate signaling cascades that ulti-
mately lead to transcriptional regulation (Yang et al., 2013). The
MLK family of kinases activates the c-jun NH2-terminal kinase
(JNK) pathway by phosphorylating MKK4 and -7 and activates
the p38 pathway by phosphorylating MKK3 and -6 (Gallo and
Johnson, 2002; Wang et al., 2004). These stress kinase complexes
required scaffold proteins in the regulation of their subcellular
localization. In particular for the MAP kinase signaling cascades,
the JNK-interacting proteins (JIPs) are the group of scaffold pro-
teins in such regulation (Kelkar et al., 2005; Whitmarsh, 2006).
Hence, these MKKs are then recruited into a multi-protein com-
plex by scaffold proteins JIPs (Habig et al., 2013). JIP1-3 regulates
the speciﬁcity and localization of the JNK pathway and JIP4 is
a speciﬁc scaffolding protein for the p38 pathway (Verhey et al.,
2001; Kelkar et al., 2005; Whitmarsh, 2006).
Multiple studies show that LRRK2 interacts with the MAPK
pathway and has a kinase domain that is homologous to MAP-
KKK/MLKs and RIPs (West et al., 2005; Greggio and Cookson,
2009; Carballo-Carbajal et al., 2010; Hsu et al., 2010a,b). However,
these same studies suggest that LRRK2 is not a strong activator
of the pathway. Our laboratory has shown that LRRK2 binds
MKK6, -3, and -7 in HEK293FT (Gloeckner et al., 2009; Hsu
et al., 2010a). Binding of LRRK2 to MKK6, -3, and -7, acti-
vates the p38 and JNK pathway, but the amount of activation
is strikingly modest (Hsu et al., 2010a). Receptor activation of
the MAPK pathway produces many fold increases in the activ-
ities of the downstream kinases, but over-expressing LRRK2
increases activities of the kinases and downstream transcrip-
tion factors by 60% or less (Hsu et al., 2010a). Studies from
the Kahle laboratory showed similarly low levels of kinase acti-
vation upon LRRK2 over-expression (Carballo-Carbajal et al.,
2010). These studies showed that LRRK2 upregulates alpha-
synuclein transcription in parallel withMEK/ERK activation. This
induction of transcriptional upregulation of alpha-synuclein was
suppressed by treatment with the selective MAPK/ERK kinase
inhibitor, U0126 (Carballo-Carbajal et al., 2010). Disease linked
mutations increased activation by only an additional 25–30%.
Similar results were observed upon analysis of JIP proteins,
which act as scaffolds for MAPKs, and function in transport of
MAPKs (Hsu et al., 2010b). We have also shown that LRRK2
binds to JIP1-4 and is associated with increased levels of total
JIP1, -3, -4, oligomeric JIP, and ubiquitinated JIP. In addition,
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G2019S, R1441C and I2020T (but not Y1699C) mutations in
LRRK2 increased binding withMKK6 and also levels of JIP4 (Hsu
et al., 2010b). The stimulation of JIP oligomerization was partic-
ularly striking effect observed upon co-expression of LRRK2 with
JIPs.
Despite the relatively modest effect of LRRK2 on the MAPK
cascades, LRRK2 produces a robust effect in vivo, and the MAPKs
appear to be necessary for this function. Our in vivo studies in C.
elegans showed robust protection againstmitochondrial stress that
was induced by LRRK2 expression. This protection was depen-
dent on the action of MKK6 or p38 because RNAi knockdown of
endogenous orthologs ofMKK6or P38 (sek-1 andpmk-1) or dele-
tion of sek-1 inC. elegans abolish neuroprotection by LRRK2 (Hsu
et al., 2010a). The MAPK cascade also appears to modulate the
effects of LRRK2 on autophagy (Plowey et al., 2008). Using redox
proteomics, we also demonstrated that LRRK2 regulates proteins
associated with the lysosome, including ATPVA6 (Di Domenico
et al., 2012). Applicationof aMAPKK(MEK) inhibitor blocked the
effects of LRRK2 on autophagy and on neurite shortening (Plowey
et al., 2008). Thus, interactions between LRRK2 and members of
the MAPK pathway cause signiﬁcant physiological effects despite
causing only modest changes in phosphorylation.
The discordance between the modest effects of LRRK2 on acti-
vation of the MAPK pathway and the strong effects of LRRK2 in
protecting dopaminergic neurons in the nematode, or the strong
effect of LRRK2 on JIP oligomerization demands a novel model
to explain LRRK2 function. One possibility is that LRRK2 acts
as a scaffold that directs the location of MAPK pathway activity,
without strongly affecting the amount of MAPK pathway activ-
ity. Location is as important to enzymatic action as amount of
activity. JIPs for instance, are thought to function in vesicular
trafﬁcking. If LRRK2 also exhibited a role in vesicular trafﬁcking,
then it could impact on neuronal function by directing particular
enzymes toward trafﬁcked vesicles, rather than explicitly activat-
ing the MAPK pathway. Such a role would also be consistent with
other studies suggesting a function for LRRK2 in regulating small
GTPases associated with vesicles.
LRRK2 REGULATES MANY OTHER SIGNALING CASCADES
Recent transcriptome and proteome studies emphasize the diverse
number of pathways regulated by LRRK2. Studies by the Dawson
group recently highlighted regulation of translational functions
by LRRK2, showing that LRRK2 binds to and phosphorylates the
ribosomal protein RPS15 (Martin et al., 2014). This observation
ﬁts well with other studies showing roles for LRRK2 as a negative
mediator of miR mediated translational repression (Gehrke et al.,
2010). The regulatory network that we developed also identiﬁes
RPS15 as a primary member of the LRRK2 regulatory network,
interacting with LRRK2 in a pathway that includes theADP-ribose
polymerase TNKS (Dusonchet et al., 2014). The Cookson group
also recently published a proteomic study of LRRK2, which identi-
ﬁed cyclin-G associated kinase (GAK) as a strong binding protein
(Beilina et al., 2014). GAK is the third strongest genetic risk factor
for PD, after synuclein and tau (Pankratz et al., 2009; Dumitriu
et al., 2011).
Other studies identify LRRK2 as a negative regulator of
PKA signaling, acting through direct interaction with PKAR11B,
modulating neuronal development and function, by inﬂuencing
dopamine signaling and synaptogenesis (Parisiadou et al., 2014).
The R1441C LRRK2mutation exhibits similar neuronal effects on
LRRK2 knockout mice, causing dopamine signaling impairments
aswell as neurite retraction via enhanced PKAactivation. PKA also
regulates LRRK2 by phosphorylating S1444 in the ROC domain;
14-3-3 then binds to the phospho-serine 1444 and inhibits LRRK2
kinase activity (Muda et al., 2014). Binding of 14-3-3 to differ-
ent phospho-epitopes (Ser-910/935) appears to stabilize LRRK2,
while reduced binding destabilizes LRRK2 and causes aggregation
of LRRK2 to form cytoplasmic inclusions (Dzamko et al., 2010).
Identiﬁcation of targets of LRRK2 kinase activity remains unclear.
Studies have identiﬁed numerous putative substrates, including
MAPK, 4E-BP, and Tau (Imai et al., 2008; Berwick and Harvey,
2011; Bailey et al., 2013).
Although LRRK2 has gained the most attention for its putative
role in modulating dopamine function, LRRK2 also exerts regu-
lation over immune responses. LRRK2 inhibits the transcription
factor NFAT, which plays important roles in immune function as
well as inﬂammatory bowel disease (Liu et al., 2011). Upon over-
expression of LRRK2, NFAT remains cytosolic, and is unable to
translocate into the nucleus, which suppresses its transcriptional
activity (Liu et al., 2011). The MyD88 pathway is an additional
pathway that is associated with the role of LRRK2 in immune
function. Upon inﬂammation, TLR signaling via theMyD88 path-
way leads to phosphorylation of LRRK2, implicating LRRK2 in
macrophage biology (Dzamko et al., 2012).
LRRK2 REGULATES SMALL GTPases
A repeating theme in LRRK2 biology is its interactions with small
GTPases. The ROC domain in LRRK2 is striking because it forms
homo- and hetero- dimers with LRRK2 and LRRK2, respectively,
in vitro (Shin et al., 2008; Hsu et al., 2010a; Kumar et al., 2010). The
tendency of the LRRK2ROCdomain to dimerize appears to belie a
broader biological characteristic, which is an ability to bindmulti-
ple small GTPases. As described below,we have shown that LRRK2
binds the small GTPase, rac1 (Chan et al., 2011). This observation
parallels other studies showing that LRRK2 binds to or is func-
tionally dependent on other small GTPases, such as rab5, rab7L1
and endoA (Matta et al., 2012; Beilina et al., 2014). Additionally,
LRRK2 bindsmultipleGTPmodulating proteins (described in fol-
lowing sections). In the case of rac1, the interactions of LRRK2
appears to regulate the site of action of the small GTPase, and
leads to strong effects on the cytoskeleton, and for arfGEF7, they
regulate the growth cone (Habig et al., 2013).
The interaction between LRRK2 and rac1 was observed by co-
immunoprecipitation. LRRK2could immunoprecipitatewith rac1
upon over-expression in cell lines (HEK293FT cells), as well as
from endogenous human brain striatum; in contrast binding to
Cdc42 was weak and binding to RhoA was not apparent (Chan
et al., 2011). Speciﬁcity of the interaction was shown by selective
precipitation of rac1, without precipitation of the other classic
Rho GTPases – Cdc42 and RhoA, although another study did
ﬁnd evidence for interaction of LRRK2 with cdc42 (Chan et al.,
2011; Habig et al., 2013). The interaction between LRRK2 and rac1
occurs through the ROC–COR kinase domains. Co-expressing
LRRK2 and rac1 enhanced rac1 activity by increasing binding
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of rac1 to p21-activated kinase, which in turn modulates actin
cytoskeletal dynamics. LRRK2 with inactivated kinase or GTPase
domains does not activate rac1 (Chan et al., 2011). LRRK2 does
not increase membrane-bound rac1, but it signiﬁcantly changes
the cellular localization of rac1, causing polarization, which
is further augmented when LRRK2 is co-expressed with con-
stitutively active rac1. G2019S and R1441C LRRK2 mutations
decrease rac1 binding; whereas Y1699C and I2020T increase rac1
binding.
Rac1 is known to play an important role in actin cytoskele-
ton remodeling that is required for the maintenance of neurite
morphology (Chan et al., 2011). The interaction between LRRK2
and rac1 results in distinct effects associated with changes in
the actin cytoskeleton. Previous studies have shown that G2019S
induces neurite retraction in both in vitro and in vivo studies
through the MAPK signaling pathway and such pathology pre-
cedes dopaminergic neuronal death by apoptosis (Liou et al., 2008;
Plowey et al., 2008; Parisiadou et al., 2009; Carballo-Carbajal et al.,
2010; Hsu et al., 2010a,b). In SH-SY5Y cells, co-expression of rac1
and G2019S has shown to rescue neurite retraction induced by
G2019S. These studies suggest that mutations in LRRK2 can lead
to a decrease in activation of rac1, which causes disassembly of
actin ﬁlaments leading to neurite retraction (Chan et al., 2011).
SYSTEMS BIOLOGY PROVIDES A COMPREHENSIVE
ASSESSMENT OF CELLULAR PATHWAYS INTERACTING
WITH LRRK2
The studies showing LRRK2 interacting with many varied cellular
proteins present a challenge forunderstanding its function. LRRK2
has been suggested to bind to many different proteins, including
moesin, tubulin,MKK3, 6 and 7, JIP1, 3, and 4, arfGAP1, arhGEF7,
endoA, cyclin-GAK, rab5, rab7L1, 14-3-3, (Imai et al., 2008; Shin
et al., 2008; Ko et al., 2009; Sancho et al., 2009; Gehrke et al., 2010;
Hsu et al., 2010a,b; Kumar et al., 2010; Nichols et al., 2010; Chan
et al., 2011; Matta et al., 2012; Stafa et al., 2012; Habig et al., 2013;
Beilina et al., 2014). LRRK2 has a regulatory role in a wide variety
of biological processes; such as, protein translations, cytoskeletal
processes, vesicular dynamics, neurite extension, mitochondrial
function, endoplasmic reticulum function, and autophagy. Broad
proteomics studies point to interactions with multiple new pro-
teins, as well as regulation of many mitochondrial and lysosomal
proteins (Di Domenico et al., 2012; Beilina et al., 2014). The mul-
tiple functions and pathways associated with LRRK2 suggest a
complex role for LRRK2 in neuronal biology.We have approached
this question by using systems biology to create a regulatory net-
work that outlines the multiplicity of functional interactions of
LRRK2 with its partners.
We employed an in silico approach to elucidate the gene reg-
ulatory network linked to LRRK2 (Dusonchet et al., 2014). This
approach used a network algorithm, termed the context likelihood
of relatedness (CLR; Faith et al., 2007). This algorithm is designed
to analyze state-dependent genome-wide expression data based
on the degree of synchrony in variation of transcript levels among
samples. Thus, transcripts whose expression varies in concert with
LRRK2 transcripts are deemed neighbors.We analyzed both brain
and white blood cells; use of white blood cells diversiﬁed the path-
way representation away from a predominance of genes linked
to cell death pathways, presumably because white blood cells are
not post-mortem tissues. The LRRK2-centered association sub-
network identiﬁed many known interactors, as well as many novel
linked pathways (Dusonchet et al., 2014). For instance, network
proteins that have been previously associated with LRRK2 are
present in this network, including DJ-1, PINK1, MKK7, and JIP1
(Ho et al., 2009; Sancho et al., 2009; Carballo-Carbajal et al., 2010;
Hsu et al., 2010a,b; Ferree et al., 2012; Dusonchet et al., 2014). The
network also identiﬁed many novel networks linked to LRRK2.
Subsequent studies validated the putative roles of these interacting
proteins using knockdown studies in C. elegans.
Previous work from the laboratory established that LRRK2
expression protects dopaminergic neurons against degeneration
induced by the mitochondrial toxin, rotenone. We tested the
action of the putative network partners in LRRK2 mediated pro-
tection of dopaminergic neurons, and identiﬁed about 280 genes
whose knockdown modiﬁed the effects of LRRK2 on dopamin-
ergic neurons. Genes whose knockdown impaired LRRK2 action
included genes known to be part of the LRRK2 network (DJ-
1, PINK1, MKK7, and JIP1), as well as multiple other genes,
including HDAC6, vps34 and unc51, each of which is associated
with autophagy (Dusonchet et al., 2014). The connection between
LRRK2 and autophagy is consistent with several other prior stud-
ies, as well as with studies suggesting a role for LRRK2 in vesicular
biology (Biskup et al., 2006; Plowey et al., 2008;Alegre-Abarrategui
et al., 2009).
One particularly interesting proteins identiﬁed through the
network analysis was the signaling gene RGS2 (regulator of G pro-
tein signaling 2), which encodes for a GTPase-activating protein
(GAP), as a statistically signiﬁcant regulatory “hub” in the path-
ways linking LRRK2 with DJ-1, PINK1, and Parkin (Dusonchet
et al., 2014). RGS2 is also of particular interest because prior
studies indicate strong expression in dopaminergic neurons. This
positioning of RGS2 as a “hub” for multiple genes linked to PD
suggests a key role for RGS2 as a regulator of LRRK2 activity,
function and neuronal toxicity (Dusonchet et al., 2014). RGS pro-
teins are a family of proteins characterized by a GAP domain
of ∼130 amino acids, the RGS domain. Other GAP proteins
have also been associated with LRRK2 function, including Arf-
GAP1 and ArhGEF7 (Stafa et al., 2012; Xiong et al., 2012; Habig
et al., 2013). Although GAPs and GTPase exchange factors (GEFs)
are classically considered to function in regulating signaling of
G-protein coupled receptors, these GAPs exhibit a strong role
in regulating LRRK2 GTPase activity. Recombinant RGS2 and
ArhGEF7 increase the GTPase activity of immunopuriﬁed full-
length LRRK2 in a dose-dependent manner in vitro. Recombinant
RGS2 also inhibits the LRRK2 kinase activity in a dose-dependent
manner. However, the concentration of RGS2 required to achieve
maximal inhibition of LRRK2 kinase activity, occurs at one tenth
of the concentration of RGS2 that is required to stimulate GTPase
activity maximally. It is increasingly clear that the output of
LRRK2 is modulated by the particular GAP or GEF bound to
it. All of the GAPs and GEFs appear to increase LRRK2 GTPase
activity, but RGS2 and ArhGEF7 reduce LRRK2 kinase activ-
ity, while ArfGAP1 increases LRRK2 autophosphorylation (Stafa
et al., 2012; Habig et al., 2013; Dusonchet et al., 2014). This sug-
gests that the output from the GTPase domain is determine, in
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part, by the particular GAP or GEF with which it is associated
(Figure 1).
GAPs AND GEFs MODULATE CYTOSKELETAL EFFECTS OF
LRRK2
A putative role for LRRK2 in regulating cytoskeletal function
consistently appears in the literature. LRRK2 has been observed
to regulate neurite outgrowth, tubulin and microtubules, traf-
ﬁcking proteins and actin (Hsu et al., 2010b; Chan et al., 2011;
Caesar et al., 2013; Law et al., 2014). Our studies suggest that
RGS2 inhibits the tendency of LRRK2 (WT and G2019S) to
reduce length and complexity of neuronal processes in primary
neurons (Figure 1; Dusonchet et al., 2014). Co-expression of
RGS2 with LRRK2 signiﬁcantly protects against G2019S LRRK2-
induced neurite shortening, although RGS2 alone has no effect
on axonal length. ArhGEF7 also increases LRRK2 GTPase activity
but induces LRRK2 to increase neuronal arborization, length and
growth cone formation (Figure 1; Habig et al., 2013). In contrast,
knockdown of ArfGAP1 protects against G2019S LRRK2-induced
neurite shortening (Figure 1; Stafa et al., 2012). ArhGEF7 acts
through the actin cytoskeleton, which raises the possibility that
it might act in tandem with rac1 and cdc42, both of which
bind LRRK2 (Chan et al., 2011; Habig et al., 2013). These data
suggest that small GTPases and their regulatory proteins act to
regulate the actions of LRRK2 on the cytoskeleton and neurite
outgrowth (Figure 1). Redundant actions of RGS2 and ArhGEF7
toward neurite cytoskeletal activity seems unlikely, which raises
the possibility that RGS2 and ArhGEF7 exhibit divergent effects
on LRRK2 when examining other functions, such as vesicular
biology.
FIGURE 1 | Regulation of LRRK2 output by GTPase activity, GAPs and
GEFs. RGS2 and ArhGEF7 both bind to LRRK2 and inhibit GTPase activity,
which also inhibits LRRK2 kinase activity and appears to direct LRRK2
toward increasing neuronal cytoskeletal activity. Rac1 is a small GTPase
known to regulate actin polymerase. Rac1 binds to LRRK2 and might act in
concert with LRRK2 to increase cytoskeletal activity. In contrast, binding of
ArfGAP1 to LRRK2 increases its autophosphorylation, which appears to
inhibit cytoskeletal activity.
CONCLUSION
LRRK2 is a largemoleculewithmanymolecular interactions.Mul-
tiple studies have focused on its kinase activity, with the resulting
identiﬁcation of LRRK2 inhibitors that might have therapeutic
beneﬁt. The function of LRRK2 kinase activity remains unclear,
with LRRK2 itself being the most robust substrate identiﬁed to
date. Meanwhile, LRRK2 has been shown to interact with many
different proteins, suggesting that important function of LRRK2
might lie in domains linked indirectly or not at all to its kinase
function. A recent study suggests that an important action of phos-
phorylation is regulation of LRRK2 degradation, which would
imply that one must look beyond kinase function to understand
the role of LRRK2 in the neuron (Skibinski et al., 2014). The need
to look beyond kinase function is emphasized by examination of
the actions of GAPs and GEFs on LRRK2, where proteins that
exhibit seemingly similar actions toward LRRK2 kinase activity
elicit opposite actions on regulation of neurite outgrowth and
cytoskeletal function (Figure 1).
Studies from our laboratory and other laboratories have iden-
tiﬁed numerous other signaling molecules that interact with
LRRK2. The interactions of LRRK2 are clearly pleiotropic, and
vary depending on the cell type and the function being investi-
gated. Despite this complexity, several distinct themes are evolving,
and these themes potentially have important implications for our
understanding of the pathophysiology of PD. One theme that
arises is the role of LRRK2 in regulating signaling cascades, such
as the MAPK cascade. It is clear that LRRK2 acts in a manner that
is different than classic modulators of the MAPK cascade, because
it does not directly stimulate phosphorylation of MAP Kinases.
The large size of LRRK2 enables it to bind multiple different pro-
teins, and potentially bring them together as a signaling scaffold,
analogous to JIPs.
A general theme occurring throughout the ﬁeld of PD is regu-
lation of vesicular transport. The vast majority of genes associated
with PD have some function related to membranes and vesicles.
α-Synuclein is thought to regulate production of small vesi-
cles by promoting membrane curvature (Perlmutter et al., 2009;
Varkey et al., 2010; Ducas and Rhoades, 2012). LRRK2 also shows
strong interactions with membranes and is thought to modu-
late autophagy, which also involves vesicular dynamics. PINK1,
parkin, and HTRA2 are all proteins that regulate mitochondrial
function, possibly includingmitophagy (Plun-Favreau et al., 2007;
Narendra et al., 2010). ATP13A2 andGBA are both associatedwith
lysosomes (Mazzulli et al., 2011; Usenovic et al., 2012). The consis-
tent appearance of vesicular biology in the pathophysiology of PD
suggests that interactions of LRRK2 with vesicles are likely to con-
tribute to its mechanism of disease pathogenesis. Future studies
will need to speciﬁcally investigate how signaling pathways regu-
late the interactions of LRRK2 with membranous organelles, such
as autophagosomes. In this context, the preliminary data show-
ing roles for the MAPK cascade in regulating the interactions of
LRRK2 with the autophagic system are intriguing (Plowey et al.,
2008).
The complexity of LRRK2 signaling provide insight into the
nature of pathology associated with LRRK2-mediated disease.
Most cases with LRRK2 mutations exhibit α-synuclein pathol-
ogy, such as Lewy bodies, but some cases exhibit tau pathology
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 64 | 5
Boon et al. LRRK2 as a regulator of cellular signaling
(Devine and Lewis, 2008). This pathological heterogeneity might
derive from the impact of different disease processes on LRRK2
biology, with some signaling cascades (such as MAPKs) promot-
ing tau pathology and other signaling cascades (such as vesicular
biology) promoting α-synuclein pathology.
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